Varies by study
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) is an intervention with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
-
Type
MIXED
Molecule
-
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
0 source entries across 0 studies. This list may not include all unresolved or historical entries.
Success Metrics
Active Trials
2(100%)
Phase Distribution
Phase 1/2
1
50%
Phase 1
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 1/2Combined phases
1(50.0%)
Highest Phase Reached
Phase 1/2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1/2
Trials by Phase
Phase 11 (50.0%)
Phase 1/21 (50.0%)
Trials by Status
active_not_recruiting2100%
Recent Activity
Clinical Trials (2)
Drug Details
- Intervention Type
- Varies by study
- Total Trials
- 2